Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

[177Lu]Lu-Prostate-specific Membrane Antigen Radioligand Therapy Combined With a PARP Inhibitor in Treatment-emergent Neuroendocrine Prostate Cancer With Rare Metastases: A New Try.

Created on 13 Nov 2026

Authors

Bingyan Shen, Yu Zhang, Xia Ou, Zhiqiao Liu, Yue Chen

Published in

Clinical nuclear medicine. Nov 11, 2026. Epub Nov 11, 2026.

Abstract

A 64-year-old man with treatment-emergent neuroendocrine prostate cancer underwent multitracer PET/CT, which demonstrated low somatostatin receptor expression but marked prostate-specific membrane antigen expression in multiple systemic lesions, including a protruding right abdominal wall metastasis. The patient subsequently received [177Lu]Lu-prostate-specific membrane antigen radioligand therapy combined with olaparib. Follow-up PET/CT showed marked reductions in tracer uptake and tumor burden, accompanied by normalization of the neuron-specific enolase level.

PMID:
43019224
Bibliographic data and abstract were imported from PubMed on 13 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 3
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement